entinostat and Adverse Drug Event studies

entinostat and Adverse Drug Event

entinostat has been researched along with Adverse Drug Event in 1 studies

Research Excerpts

Excerpt	Relevance	Reference
"Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes."	5.46	Entinostat: a promising treatment option for patients with advanced breast cancer. ( Connolly, RM; Piekarz, R; Rudek, MA, 2017)
"Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes."	1.46	Entinostat: a promising treatment option for patients with advanced breast cancer. ( Connolly, RM; Piekarz, R; Rudek, MA, 2017)

Research

Studies (1)

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Studies

Connolly, RM

Rudek, MA

Piekarz, R

Other Studies

1 other study available for entinostat and Adverse Drug Event

Article	Year
Entinostat: a promising treatment option for patients with advanced breast cancer. Future oncology (London, England), 2017, Volume: 13, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Breast Neoplasms; Cell Line,	2017

Article

Year

Future oncology (London, England), 2017, Volume: 13, Issue:13

Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Breast Neoplasms; Cell Line,

2017